Nalaganje...
Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
Melanoma frequently harbors oncogenic mutations in the BRAF gene, which drives melanoma growth. Therefore, BRAF kinase inhibitors (BRAFi) are developed and approved for treating BRAF-mutant melanoma. However, the efficacy of BRAFi is limited due to acquired resistance, and in over 40% of melanoma, t...
Shranjeno v:
| izdano v: | iScience |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6593146/ https://ncbi.nlm.nih.gov/pubmed/31229894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2019.06.001 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|